Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 07 March 2016 | By Zachary Brennan
Counterfeits of Gilead’s mega-blockbuster hepatitis C treatment Harvoni, which is generating billions per quarter in sales for the company, are emerging in Israel.
Switzerland’s drug regulator Swissmedic said over the weekend that the plastic bottles of the counterfeits, which originated in India, were imported via a Swiss trading company and “contain white instead of genuine yellow film-coated tablets,” the regulator said.
Swissmedic is working with other EU authorities to establish whether Harvoni packs with counterfeit contents have also been imported into other countries.
The counterfeit versions of the hepatitis C treatment, which have a list price in the US of $94,500 for a 12-week regimen, come as Swissmedic acknowledges that many Swiss patients are purchasing Harvoni abroad because of the price is dramatically lower in other countries like India and Egypt.
The discovery of counterfeit Harvoni comes as hepatitis C patients in the US and EU are increasingly coming up with unique ways to obtain Gilead’s drugs, which are sold for a fraction of the US list price in other countries. In October, Gilead reported Q3 sales of $4.8 billion for its two hepatitis C drugs.
Swissmedic advises against purchasing any medicine from unknown sources, and particularly against ordering them via the Internet.
“There is no guarantee that medicines sold at very low prices from countries with no comparable medicines control system actually contain the declared active ingredient or the correct dosage of that active ingredient,” Swissmedic said.
The Drug Regulatory Authority of Pakistan (DRAP) also has uncovered illegal manufacturing of Gilead’s other hepatitis C product Sovaldi (sofosbuvir).
Gilead in 2014 licensed 11 generic Indian drugmakers, including Hetero Labs, Cipla and Aurobindo Pharma, to make and sell generic versions of Sovaldi in almost 100 developing countries, and Mylan has already launched its generic version. The company has also said it would launch its own branded version of Sovaldi in India at a price of $300 per month.Swissmedic Announcement
Tags: Harvoni, Sovaldi, Gilead, Hepatitis C drug fakes, fake drugs online
Regulatory Focus newsletters
All the biggest regulatory news and happenings.